-
Mashup Score: 2
Adjuvant mitotane might not be indicated in patients with low-grade, localised adrenocortical carcinoma considering the relatively good prognosis of these patients, and no significant improvement in recurrence-free survival and treatment-associated toxicity in the mitotane group. However, the study was discontinued prematurely due to slow recruitment and cannot rule out an efficacy of treatment.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0
Recently, a man aged 50 years came to my office. He had received surgery for a right-sided non-functional adrenocortical carcinoma measuring 11 cm in diameter and had been referred to discuss adjuvant treatment. Based on adrenal histology findings, he had a European Network for the Study of Adrenal Tumors (ENS@T) tumour stage II, which means no lymph node metastases, and a [18F]fluorodeoxyglucose-PET scan had ruled out distant metastasis.1 Fortunately, he had undergone oncological tumour resection resulting in complete resection.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0
Single-cell and spatial transcriptomics reveal the proximity of mesenchymal tumor cells to myofibroblastic cancer-associated fibroblasts and their association with disease outcome and immune checkpoint inhibitor response in clear cell renal cell carcinoma.
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
In a pan-cancer analysis, patients with pancreatic acinar cell carcinoma had the highest prevalence of BRCA2 germline pathogenic variants.
Source: www.cancertherapyadvisor.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4
Adjuvant mitotane might not be indicated in patients with low-grade, localised adrenocortical carcinoma considering the relatively good prognosis of these patients, and no significant improvement in recurrence-free survival and treatment-associated toxicity in the mitotane group. However, the study was discontinued prematurely due to slow recruitment and cannot rule out an efficacy of treatment.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 1
Recently, a man aged 50 years came to my office. He had received surgery for a right-sided non-functional adrenocortical carcinoma measuring 11 cm in diameter and had been referred to discuss adjuvant treatment. Based on adrenal histology findings, he had a European Network for the Study of Adrenal Tumors (ENS@T) tumour stage II, which means no lymph node metastases, and a [18F]fluorodeoxyglucose-PET scan had ruled out distant metastasis.1 Fortunately, he had undergone oncological tumour resection resulting in complete resection.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 5
Adjuvant mitotane might not be indicated in patients with low-grade, localised adrenocortical carcinoma considering the relatively good prognosis of these patients, and no significant improvement in recurrence-free survival and treatment-associated toxicity in the mitotane group. However, the study was discontinued prematurely due to slow recruitment and cannot rule out an efficacy of treatment.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 2
Adjuvant mitotane might not be indicated in patients with low-grade, localised adrenocortical carcinoma considering the relatively good prognosis of these patients, and no significant improvement in recurrence-free survival and treatment-associated toxicity in the mitotane group. However, the study was discontinued prematurely due to slow recruitment and cannot rule out an efficacy of treatment.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Patients with sarcomatoid and/or rhabdoid metastatic non-clear cell renal cell carcinoma are known to have poor clinical outcomes. Studies found potential benefits of immunotherapy-based regimens for this patient population: https://t.co/36Ffv4hNfm #RenalCancer #Carcinoma #ASCO https://t.co/m64AjfhW3z
-
-
Mashup Score: 0
Adjuvant mitotane might not be indicated in patients with low-grade, localised adrenocortical carcinoma considering the relatively good prognosis of these patients, and no significant improvement in recurrence-free survival and treatment-associated toxicity in the mitotane group. However, the study was discontinued prematurely due to slow recruitment and cannot rule out an efficacy of treatment.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
In the October Issue: #Adjuvant #mitotane versus #surveillance in low-grade, localised #adrenocortical #carcinoma (#ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study https://t.co/Ujp2h9u9hd #adrenal #ACC #OpenAccess